Tirzepatide Beats Semaglutide With 21.6% Weight Loss
The SURMOUNT-5 trial found tirzepatide cut body weight by 21.6% on average versus 15.4% for semaglutide over 72 weeks in adults with obesity but no diabetes.
Tag
semaglutide
India DCC Tightens Curbs on GLP-1 Drug Advertising
India's Drugs Consultative Committee flagged surrogate and misleading advertising of GLP-1 obesity drugs like Semaglutide at its 68th meeting, recommending tighter enforcement by State Drug Controllers. The move follows a March 10, 2026, CDSCO advisory prohibiting public-directed promotion of prescription-only GLP-1
← Back
Tag
semaglutide
SURMOUNT-5 Trial: Tirzepatide vs Semaglutide in Obesity Management
The SURMOUNT-5 trial found tirzepatide cut body weight by 21.6% on average versus 15.4% for semaglutide over 72 weeks in adults with obesity but no diabetes.
1mo ago · 3 min · Big Stories
No Ads for Prescription Drugs: Panel Flags Surrogate Advertising, Misleading Promotions of GLP-1 Obesity Drugs
India's Drugs Consultative Committee flagged surrogate and misleading advertising of GLP-1 obesity drugs like Semaglutide at its 68th meeting, recommending tighter enforcement by State Drug Controllers. The move follows a March 10, 2026, CDSCO advisory prohibiting public-directed promotion of prescription-only GLP-1
2mo ago · 1 min · Policy & Government
— End of feed —